RegeneRx Biopharmaceuticals, Inc. · OTC:RGRX
RegeneRx Biopharmaceuticals — Investor Presentation (October 2008)
31 slides from RegeneRx Biopharmaceuticals's investor presentation, Oct 30, 2008
Slide 1: Corporate Presentation Q4 2008
Version 36 Corporate Presentation Q4 2008
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Examp
Slide 3: Company Overview
3 Company Overview Company founded in 1982 - Tß4 development initiated in 2000 with license from NIH Publicly-traded biopharmaceutical company - American Stock exchange – Symbol: RGN Based in Bethesda, MD - 11 employees Employs an outsourcing business model - Small, manageable infrastructure 4 drug
Slide 4: RGN value proposition
4 RGN value proposition Tß4 is a critical component of tissue protection & repair Numerous published studies show Tß4’s broad biological activities Multiple Tß4 formulations developed to optimize clinical potential RGN expects to report clinical data over next 12 months - RGN-137 phase II dermal cli
Slide 5: Multiple drug formulations – in clinical trials, preclinical
5 Multiple drug formulations – 3 in clinical trials, 1 preclinical - Topical gel / RGN-137 - Eye drops / RGN-259 - Parenteral / RGN-352 - Inhalation / RGN-457 Clinical trials focused on tissue protection and repair - 3 dermal phase II wound healing trials / RGN-137 - Ophthalmic phase II wound healin
Slide 6: Tß4 key tissue protection and repair molecule
6 Tß4 key tissue protection and repair molecule 43-amino acid peptide Synthetic copy of naturally occurring, conserved molecule – not a growth factor Found in most cells but not red blood cells1 Highest concentration in blood platelets,3 white blood cells and macrophages First gene to up-regulate wh
Slide 7: Dermal RGN-137
7 Dermal RGN-137
Slide 8: RGN-137 accelerates dermal tissue repair in rats
8 RGN-137 accelerates dermal tissue repair in rats Re-epithelialization Anti-inflammation Malinda et al, Thymosin B4 Accelerates Wound Healing, The Soc for Inv Derm, 1999 Angiogenesis Collagen Deposition acceleration Control Topical I.P. Biologic Activities 1. Re-epithelialization 2. Anti-Inflammati
Slide 9: RGN-137 phase II data expected in Dec 2008 & 2009
9 RGN-137 phase II data expected in Dec 2008 & 2009 Phase I dermal safety - 15 healthy volunteers - Safe and well-tolerated Phase II pressure ulcers - 72-patient trial at 19 U.S. sites - Randomized, double-blind, placebo-controlled, dose-escalation, 84-day treatment - Target enrollment completed - D
Slide 10: Ophthalmic RGN-259
Ophthalmic RGN-259 REGENERX
Slide 11: RGN-259 accelerates tissue repair after eye injury in mice
11 RGN-259 accelerates tissue repair after eye injury in mice Sosne et. el., TB4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury, Exp Eye Res, 2002 Inflammatory Cells Re-epithelialization Biologic Activities 1. Reduced Inflammation (NFkB, TNF alpha, IL-1B, I
Slide 12: RGN-259 shows signs of human efficacy
12 RGN-259 shows signs of human efficacy First “Compassionate Use” of RGN-259 Patient: - Middle age female - Severe diabetic - Serious cardiac and liver disease - Underwent Vitrectomy surgery - Non-healing cornea after 23 days post surgery - Wound healed after topical administration of Tß4 by day 11
Slide 13: RGN-259 proof of concept trial - data expected in 2009
13 RGN-259 proof of concept trial - data expected in 2009 No phase I ophthalmic study required - Per discussion with the FDA Ophthalmic Review Committee - Based on safety of all non-clinical studies and topical dermal formulation Phase II corneal wound healing post-vitrectomy - 36-patient trial – en
Slide 14: RGN-259, compassionate use ophthalmic patients
14 RGN-259, 5 compassionate use ophthalmic patients First compassionate IND, 1 patient - Completed treatment in Q2 2006 - 1 patient, severe diabetic - Non-healing cornea after 23 days post surgery - Immediate reduction of irritation and inflammation - Wound healed after topical administration of Tß4
Slide 15: Cardiovascular RGN-352
15 Cardiovascular RGN-352
Slide 16: Tß4’s (RGN-352) powerful preclinical cardiac data
16 Tß4’s (RGN-352) powerful preclinical cardiac data Statistically significant improvement in ventricular function (p<0.0001) in mouse heart failure model 7 Statistically significant reduction in ventricular scarring (p<0.02) after acute myocardial infarction (M.I.) when administered within 24 hours
Slide 17: RGN-352 reduces heart damage after injury in mice
18 RGN-352 reduces heart damage after injury in mice Bock-Marquette, et. al, Thymosin B4 activates integrin-linked kinase and promotes cardiac cell migration, survival and repair, NATURE, 2004 p < 0.02 ~53% Reduction in Scar Volume Biologic Activities 1. Prevents apoptosis 2. Enhanced myocardial sal
Slide 18: RGN-352 phase IB safety data expected in Q1 2009
19 RGN-352 phase IB safety data expected in Q1 2009 Phase I - Two components: phase IA and IB - Normal healthy volunteers - 40 subjects in each phase - Randomized, double-blind, placebo-controlled, dose response - Target enrollment completion: • IA – Completed in Q3 2008 • IB – Completion in Q1 2009
Slide 19: RGN Sponsoring trials for multiple indications
21 RGN Sponsoring 5 trials for multiple indications Indications Preclinical Phase I Phase II Data targeted Pressure Ulcers (72 patients) Venous Stasis Ulcers (72 patients) Epidermolysis Bullosa (36 patients) Corneal Wound Healing associated with diabetic vitrectomy surgery (36 patients) Acute Myocar
Slide 20: RGN’s product development pipeline
22 RGN’s product development pipeline Indications Research/PC Phase I Phase II Phase III Pressure Ulcers Venous Stasis Ulcers Epidermolysis Bullosa Diabetic Foot Ulcers Burns Corneal Wounds Recurrent Corneal Erosions Corneal Surgeries Sjögren’s Dry Eye Acute Myocardial Infarction Ischemic Stroke Isc
Slide 21: Market Opportunities & Partnering Strategy
23 Market Opportunities & Partnering Strategy
Slide 22: Multiple formulations broaden potential pipeline
24 Multiple formulations broaden potential pipeline US Treatable Populations and Market Values based on RegeneRx market research and price, dose, regimen assumptions. There is no assurance that these figures are accurate now or will be accurate if and when RegeneRx has commercialized a product that
Slide 23: RGN focused on licensing and partnering strategies
25 RGN focused on licensing and partnering strategies that optimize commercialization RegeneRx’s strategy is to develop and commercialize RGN-137 and RGN-352 for EB topical and injectable use Out-license rights for all other indications for development and commercialization - Topical RGN-137 - Ophth
Slide 24: Summary
26 Summary Tß4 is a critical component of tissue protection & repair Numerous published studies show Tß4’s broad biological activities Multiple Tß4 formulations developed to optimize clinical potential RGN expects to report clinical data over next 12 months - RGN-137 phase II dermal clinical data ex
Slide 25: Appendix
27 Appendix
Slide 26: Bibliography
28 Bibliography 1. Huff T et al., (2001) ß-Thymosins, small acetic peptides with multiple functions, Int. J. Biochem. Cell Biol., 33, 205-220. 2. Grant DS et. al.,(1995) Matrigel induces thymosin ß4 gene in differentiating endothelial cells. J. Cell Sci. 108, 3685-3694. 3. Huff T et. al., (2002) Thy
Slide 27: Management
29 Management Dr. Allan Goldstein – Chairman & Chief Scientific Advisor - Founder of RegeneRx, Discoverer of T a 1 and Tß4 - Chairman of Biochemistry and Molecular Biology, George Washington Univ School of Medicine - Author of over 400 scientific articles; inventor of more than 25 U.S. Patents J.J.
Slide 28: Scientific Advisory Board
30 Scientific Advisory Board Allan Goldstein, PhD – Chairman & Chief Scientific Advisor - Professor and Chair, Dept of Biochemistry and Molecular Biochemistry, GWU Med School, Washington, DC Herve Byron, MD, MSc - Ophthalmologist, editorial board of several ophthalmic journals, New York, NY Paolo Ca
Slide 29: RGN has a broad patent portfolio
31 RGN has a broad patent portfolio Obtained world-wide intellectual property rights under an exclusive license from NIH in 1999 Granted or applied for over 60 world-wide patents related to Tß4, active fragments, compositions of matter, combinations, uses and methods of delivery Patents expire from
Slide 30: Manufacturing Overview
32 Manufacturing Overview All formulated drug candidates and API designed to meet long-term requirements for clinical and commercial use API manufactured under cGMP by solid-phase peptide synthesis Three drug product formulations have been developed and being used in the clinic Fourth formulation un
Slide 31: Preclinical studies show multiple key MOAs for Tß4
33 Preclinical studies show multiple key MOAs for Tß4 Tissue Sites Biological Activities Mechanisms of Action Dermis, Myocardium, Cornea Promotes cell migration l,2,4,6 Regulates F- and G-actin Dermis, Myocardium Promotes angiogenesis and stem cell differentiation 2,5,7,11 Unknown Dermis Accelerates
Regenerx Biopharmaceuticals — Investor Presentation (October 2008) on 6ix